316 related articles for article (PubMed ID: 23188827)
21. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
[TBL] [Abstract][Full Text] [Related]
22. Species-specific differences in the processing of acid α-glucosidase are due to the amino acid identity at position 201.
Moreland RJ; Higgins S; Zhou A; VanStraten P; Cauthron RD; Brem M; McLarty BJ; Kudo M; Canfield WM
Gene; 2012 Jan; 491(1):25-30. PubMed ID: 21963446
[TBL] [Abstract][Full Text] [Related]
23. Conjugation of mannose 6-phosphate-containing oligosaccharides to acid alpha-glucosidase improves the clearance of glycogen in pompe mice.
Zhu Y; Li X; Kyazike J; Zhou Q; Thurberg BL; Raben N; Mattaliano RJ; Cheng SH
J Biol Chem; 2004 Nov; 279(48):50336-41. PubMed ID: 15383547
[TBL] [Abstract][Full Text] [Related]
24. Biochemical and pharmacological characterization of different recombinant acid alpha-glucosidase preparations evaluated for the treatment of Pompe disease.
McVie-Wylie AJ; Lee KL; Qiu H; Jin X; Do H; Gotschall R; Thurberg BL; Rogers C; Raben N; O'Callaghan M; Canfield W; Andrews L; McPherson JM; Mattaliano RJ
Mol Genet Metab; 2008 Aug; 94(4):448-455. PubMed ID: 18538603
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficacy of an AAV vector encoding chimeric, highly secreted acid alpha-glucosidase in glycogen storage disease type II.
Sun B; Zhang H; Benjamin DK; Brown T; Bird A; Young SP; McVie-Wylie A; Chen YT; Koeberl DD
Mol Ther; 2006 Dec; 14(6):822-30. PubMed ID: 16987711
[TBL] [Abstract][Full Text] [Related]
26. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
[TBL] [Abstract][Full Text] [Related]
27. Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.
Kishnani P; Tarnopolsky M; Roberts M; Sivakumar K; Dasouki M; Dimachkie MM; Finanger E; Goker-Alpan O; Guter KA; Mozaffar T; Pervaiz MA; Laforet P; Levine T; Adera M; Lazauskas R; Sitaraman S; Khanna R; Benjamin E; Feng J; Flanagan JJ; Barth J; Barlow C; Lockhart DJ; Valenzano KJ; Boudes P; Johnson FK; Byrne B
Mol Ther; 2017 May; 25(5):1199-1208. PubMed ID: 28341561
[TBL] [Abstract][Full Text] [Related]
28. Synergistic Efficacy from Gene Therapy with Coreceptor Blockade and a β2-Agonist in Murine Pompe Disease.
Han SO; Li S; Bird A; Koeberl D
Hum Gene Ther; 2015 Nov; 26(11):743-50. PubMed ID: 26417913
[TBL] [Abstract][Full Text] [Related]
29. Muscle as a putative producer of acid alpha-glucosidase for glycogenosis type II gene therapy.
Martin-Touaux E; Puech JP; Château D; Emiliani C; Kremer EJ; Raben N; Tancini B; Orlacchio A; Kahn A; Poenaru L
Hum Mol Genet; 2002 Jul; 11(14):1637-45. PubMed ID: 12075008
[TBL] [Abstract][Full Text] [Related]
30. Glycoengineered acid alpha-glucosidase with improved efficacy at correcting the metabolic aberrations and motor function deficits in a mouse model of Pompe disease.
Zhu Y; Jiang JL; Gumlaw NK; Zhang J; Bercury SD; Ziegler RJ; Lee K; Kudo M; Canfield WM; Edmunds T; Jiang C; Mattaliano RJ; Cheng SH
Mol Ther; 2009 Jun; 17(6):954-63. PubMed ID: 19277015
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of antihypertensive drugs in combination with enzyme replacement therapy in mice with Pompe disease.
Han SO; Haynes AC; Li S; Abraham DM; Kishnani PS; Steet R; Koeberl DD
Mol Genet Metab; 2020 Feb; 129(2):73-79. PubMed ID: 31645300
[TBL] [Abstract][Full Text] [Related]
32. Oral delivery of Acid Alpha Glucosidase epitopes expressed in plant chloroplasts suppresses antibody formation in treatment of Pompe mice.
Su J; Sherman A; Doerfler PA; Byrne BJ; Herzog RW; Daniell H
Plant Biotechnol J; 2015 Oct; 13(8):1023-32. PubMed ID: 26053072
[TBL] [Abstract][Full Text] [Related]
33. Novel GAA sequence variant c.1211 A>G reduces enzyme activity but not protein expression in infantile and adult onset Pompe disease.
Nilsson MI; Kroos MA; Reuser AJ; Hatcher E; Akhtar M; McCready ME; Tarnopolsky MA
Gene; 2014 Mar; 537(1):41-5. PubMed ID: 24384324
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of glycogen biosynthesis via mTORC1 suppression as an adjunct therapy for Pompe disease.
Ashe KM; Taylor KM; Chu Q; Meyers E; Ellis A; Jingozyan V; Klinger K; Finn PF; Cooper CG; Chuang WL; Marshall J; McPherson JM; Mattaliano RJ; Cheng SH; Scheule RK; Moreland RJ
Mol Genet Metab; 2010 Aug; 100(4):309-15. PubMed ID: 20554235
[TBL] [Abstract][Full Text] [Related]
35. Salmeterol enhances the cardiac response to gene therapy in Pompe disease.
Han SO; Li S; Koeberl DD
Mol Genet Metab; 2016 May; 118(1):35-40. PubMed ID: 27017193
[TBL] [Abstract][Full Text] [Related]
36. Intercellular transfer of the virally derived precursor form of acid alpha-glucosidase corrects the enzyme deficiency in inherited cardioskeletal myopathy Pompe disease.
Pauly DF; Fraites TJ; Toma C; Bayes HS; Huie ML; Hirschhorn R; Plotz PH; Raben N; Kessler PD; Byrne BJ
Hum Gene Ther; 2001 Mar; 12(5):527-38. PubMed ID: 11268285
[TBL] [Abstract][Full Text] [Related]
37. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
38. Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease.
Cousens LP; Mingozzi F; van der Marel S; Su Y; Garman R; Ferreira V; Martin W; Scott DW; De Groot AS
Hum Vaccin Immunother; 2012 Oct; 8(10):1459-64. PubMed ID: 23095864
[TBL] [Abstract][Full Text] [Related]
39. Airway smooth muscle dysfunction in Pompe (
Keeler AM; Liu D; Zieger M; Xiong L; Salemi J; Bellvé K; Byrne BJ; Fuller DD; ZhuGe R; ElMallah MK
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L873-L881. PubMed ID: 28336814
[TBL] [Abstract][Full Text] [Related]
40. A study on the safety and efficacy of reveglucosidase alfa in patients with late-onset Pompe disease.
Byrne BJ; Geberhiwot T; Barshop BA; Barohn R; Hughes D; Bratkovic D; Desnuelle C; Laforet P; Mengel E; Roberts M; Haroldsen P; Reilley K; Jayaram K; Yang K; Walsh L;
Orphanet J Rare Dis; 2017 Aug; 12(1):144. PubMed ID: 28838325
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]